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Background: There is a need for a disease-specific instrument for assessing health-related quality of life in adults
with hereditary angioedema due to C1 inhibitor deficiency, a rare, disabling and life-threatening disease. In this
paper we report the protocol for the development and validation of a specific questionnaire, with details on
the results of the process of item generation, domain selection, and the expert and patient rating phase.
Methods/Design: Semi-structured interviews were completed by 45 patients with hereditary angioedema and 8
experts from 8 regions in Spain. A qualitative content analysis of the responses was carried out. Issues raised by
respondents were grouped into categories. Content analysis identified 240 different responses, which were
grouped into 10 conceptual domains. Sixty- four items were generated. A total of 8 experts and 16 patients
assessed the items for clarity, relevance to the disease, and correct dimension assignment. The preliminary
version of the specific health-related quality of life questionnaire for hereditary angioedema (HAE-QoL v 1.1)
contained 44 items grouped into 9 domains.
Discussion: To the best of our knowledge, this is the first multi-centre research project that aims to develop a
specific health-related quality of life questionnaire for adult patients with hereditary angioedema due to C1
inhibitor deficiency. A preliminary version of the specific HAE-QoL questionnaire was obtained. The qualitative
analysis of interviews together with the expert and patient rating phase helped to ensure content validity.
A pilot study will be performed to assess the psychometric properties of the questionnaire and to decide on
the final version.
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Hereditary angioedema due to C1 inhibitor deficiency
(HAE-C1-INH) is a genetic disease that reduces the
synthesis or function of C1 inhibitor (C1-INH) [1].
Bradykinin acts as the primary mediator [2]. It is con-
sidered a rare disease, and in Spain has a minimal
prevalence rate of 1.09 cases/100,000 inhabitants [3].
HAE-C1-INH is characterized by recurrent edema
attacks affecting different parts of the body (e.g.: face,
extremities, gastrointestinal track, upper airway) [1,4].
The clinical expression is quite variable; patients may be
asymptomatic or suffer from life-threatening angioe-
dema episodes with a wide range of disabling symptoms,
severe pain or disfigurement. Attacks are unpredictable.
Abdominal attacks may mimic acute abdominal emer-
gencies, prompting unnecessary surgery. Mortality is
mainly due to upper airway obstruction caused by laryn-
geal edema and has been reported to be as high as 30-
50% in patients with undiagnosed HAE-C1-INH [4] and
30% in patients diagnosed with HAE-C1-INH whose
cases were improperly treated [5].
Conventional treatment for allergic angioedema with
adrenaline, antihistamines and glucocorticoids has not
been shown efficacious [6].
Therapeutic management of HAE-C1-INH focuses on
either preventing or treating attacks. Although new
drugs have been developed in recent years, their avail-
ability differs from country to country and may even
vary among hospitals within a country. Attenuated
androgens, antifibrynolytics and plasma derived human
C1 inhibitor concentrate (pdhC1INH) are the most com-
monly used drugs for long term prophylactic treatment.
Election treatment for acute episodes are replacement of
the lacking protein (pdhC1INH, nanofiltered pdhC1INH
or recombinant C1INH concentrate), icatibant acetate or
ecallantide and fresh frozen plasma when the aforemen-
tioned treatments are not available [7]. Different consen-
sus guidelines for management of HAE-C1-INH have
been published [7-13]. Several drug adverse effects and
contraindications have been reported (see Table 1).
The unavailability of some HAE-C1-INH specific ther-
apies, as well as the potential side effects and contraindi-
cations of treatments could significantly hinder the
management of HAE-C1-INH patients. Moreover, the
lack of awareness of HAE-C1-INH among health care
professionals may cause patients to fear for their safety
and could have a negative effect on health-related Qual-
ity of Life (HRQoL).
HRQoL is considered to be a subjective assessment of
the impact of disease and treatment across physical, psy-
chological, social and somatic domains of functioning
and well-being [23]. Several aspects of HAE-C1-INH
(hereditary transmission, improper diagnosis, unpre-
dictability of attacks, disabling symptoms, risk of fatalattacks, unnecessary surgeries, inadequate treatments,
frequent need for emergency intervention, lack of infor-
mation about the disease among health care profes-
sionals, adverse effects of treatment or unavailability of
specific treatment, etc.) could diminish HRQoL, and the
impact of HAE-C1-INH on quality of life should be
evaluated. However, there is limited data on this topic in
the published literature [24-28]. To the best of
our knowledge, a specific instrument for assessing the
impact of HAE-C1-INH on HRQoL has not yet been
made available.
This HAE-QoL project aims to develop a sound
psychometric tool with which to assess HRQoL in
HAE-C1-INH. It has been designed with two phases: the
first was for developing the draft version of the question-
naire and the remaining phase will be for assessing its
psychometric characteristics. Once the instrument has
been validated, we will perform a HRQoL study using
the final version of the questionnaire.
The results derived from the first phase of the study,
in which domains were chosen and items were identified
for the first draft of the HAE-QoL questionnaire, are
described in this manuscript. We have also included the
results of the expert and patient rating phase in which
we received feedback for assessing both content and face
validity. Lastly, this paper contains the protocol for the
future pilot study and psychometric analysis.
Methods and design
Ethical approval was granted by the Research Ethics
Committee of Hospital Universitario La Paz (Madrid).
HAE-C1-INH patients 18 years or older and HAE-C1-INH
experts from different regions of Spain participated in the
study. Inclusion criteria for patients, were that they
be 18 years old or older and have a confirmed
laboratory diagnosis of HAE-C1-INH (type I or II).
Exclusion criteria were cognitive disabilities and lack of flu-
ency in Spanish language.
Participating patients signed an informed consent
form. An in-house scoring system for classifying the
severity of HAE-C1-INH (asymptomatic, mild, moderate
and severe) in patients was established by taking into
account the frequency of symptoms, the occurrence of
life-threatening angioedema attacks and the need for
maintenance therapy (see Table 2). For this step, a con-
venience sample was formed with patients with different
degrees of disease severity. A main priority was to
include subjects with the most severe clinical expression
since they were the ones who theoretically would suffer
a greater burden on their QoL.
The questionnaire was developed according to stand-
ard questionnaire development guidelines and method-
ologies, as well as the protocol for development of a
specific HRQoL questionnaire for hemophilia, a disease
Table 1 Secondary adverse events and contraindications of treatments in HAE-C1-INH
Drug Secondary Adverse Events Contraindications
Attenuated androgens Virilization, headache, depression, weight gain,
menstrual irregularities, sleeplessness, agitation,
mood changes, arterial hypertension, dyslipemia,
decreased libido and hepatotoxiciy [14-17].
Pregnancy, lactation, childhood, breast cancer,
prostate carcinoma, nephrotic syndrome, significant
alteration of hepatic function [7].
Antifibrinolytics Nausea, vomiting, headache, diarrhea, orthostatic
regulation disturbances, myositis, muscle necrosis,
increase in the risk of thrombosis [1].
History of thrombosis or thromboembolism [7].
Fresh frozen plasma Transmission of infectious diseases, potential aggravation
of edema symptoms due to substrate supply that may
lead to an increase of bradykinin, alloimmunization,
anaphylactic or allergic reactions, excessive intravascular
volume with risk of hypervolemia and heart failure [7].
pdhC1INH Potential transmission of infectious and/or pathogenic
viruses [18], infection at injection site and thrombosis
associated with indwelling catheters used for the
administration of long-term prophylaxis with pdhC1inh
concentrate [12].
Icatibant acetate Minor local adverse effects (self-limited erythema,
pruritus and pain in injection area) [19,20].
Active ischemic heart diseaseIctus in previous
2 weeks [20].
Ecallantide Anaphylactic and other acute allergic reactions [21]
Recombinant human C1INH Allergic reaction [22]. Rabbit allergy [7].
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A patient-centred perspective based on a qualitative
methodology was chosen in order to ensure that the
content was appropiate and relevant for the target popu-
lation and did not omit any issues of importance to the
HAE-C1-INH patient.
Semi-structured individual interviews of HAE-C1-INH
patients and experts were conducted using a written
self-administered questionnaire. Subjects were asked 8
questions about their personal views on the disease
(Table 3). Answers were transcribed and a qualitative
content analysis of the responses was carried out accord-
ing to published methodology [33,34], in order to build
a theoretical model. The procedure followed an induct-
ive approach whereby transcripts were encoded in order
to develop conceptual categories (domains), in which toTable 2 Severity Score (over the last year)
Severity Score Criteria
ASYMPTOMATIC No angioedema episodes and no long term
prophylactic treatment.
MILD No life-threatening angioedema episodes,
no long term prophylactic treatment and
≤ 6 episodes/year.
MODERATE No life-threatening angioedema episodes
and≤ 12 episodes/year with long term
prophylactic treatment (exclude maintenance
treatment with pdhC1INH) or> 6 episodes/
year without long term prophylactic treatment.
SEVERE Life-threatening angioedema episode and/or
> 12 episodes/year with long
term prophylactic treatment and/or maintenance
treatment with pdhC1INH.classify issues that appeared in the data. Identified
responses were organized in terms of frequency and
issue, and common issues were grouped into domains.
Lastly, items were generated using the reports on the
verbatims from patients and experts. Every procedure
was double checked by at least two members of the re-
search team in order to ensure accuracy.
Our HAE-C1-INH patient group (29 females and 16
males) had a mean age of 39 years (18–74 years) and dif-
ferent degrees of HAE-C1-INH severity. These patients
and the 8 HAE-C1-INH experts who participated in the
study came from 8 regions of Spain (Madrid, Andalusia,
Catalonia, Galicia, Asturias, the Valencian Community,
Castille and Leon, and the Basque Country).
A content analysis of the interviews identified 240 dif-
ferent responses (verbatims). Subjects referred to relation-
ships with health care professionals, work, studies, family,
leisure activities, sport, travel, aesthetics, emotional life,
sex life, fear of a fatal episode, death of relatives, and
treatment (side effects, availability, and new therapies).
The most representative verbatim reports were used to
formulate questions for developing an optimal item pool
(examples are shown in Table 4). Content analysis led to
the creation of 10 conceptual categories or domains:
health conditions, physical functioning, social role, emo-
tional role, physical role, symptoms, general health, aes-
thetics, mental health and treatment. A set of 64 items
was developed and they were grouped into these domains.
A theoretical model of the questionnaire was built based
on these domains and served as the basis for the draft ver-
sion of the HRQoL questionnaire (HAE-QoL v 1.0). A 5
or 6-point Likert scale (or summative scale) will be used.
Table 3 Qualitative interviewing: semi-structured questions answered in interviews with HAE-C1-INH patients and
experts
Questions for HAE-C1-INH patients
1 Without using medical or technical terms, how would you describe your disease?
2 Name the five aspects of your life that are most important to you.
1 Of the aspects you have mentioned, which one is the most affected by your disease at this time?
2 What bothers you most about your disease?
3 What worries you most about your disease?
4 What has made you feel upset, pensive or annoyed in relation to your disease?
5 In what ways does your disease limit you?
6 Is there anything else that you would like to add about your disease?
Questions for HAE-C1-INH experts:
1 Without using medical or technical terms, how would you describe HAE-C1-INH?
2 Name the five aspects of life that in your opinion are the most important for a HAE-C1-INH patient.
3 Of the aspects you have mentioned, which one is the most affected by HAE-C1-INH?
4 In your opinion, what aspect of the disease most bothers a HAE-C1-INH patient?
5 What do you think most worries a HAE-C1-INH patient about his/her disease?
6 What do you think makes a HAE-C1-INH patient feel upset, pensive or annoyed in relation with
his/her disease?
7 In what ways does the disease limit a HAE-C1-INH patient?
8 Is there anything else that you would like to add about HAE-C1-INH?
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questionnaire and the number of items per domain in
the draft version are shown in Table 5.
In order to assess the content and face validity of the
questionnaire, the draft version was initially evaluated byTable 4 Examples of significant units (verbatims) and items
Significant units (Verbatims) Domains
“Few doctors know about my disease” Health co
“I am worried about transmitting the disease to my children” Emotiona
“I feel insecure when traveling, due to the unavailability of
C1 inhibitor concentrate”
Social role
“The truth is that I am always frightened” Mental He
“I am worried about the adverse side effects of medication” Treatmen
“An important aspect that is affected is work. Attacks are more
frequent at exam time”
Physical ro
“Barrier to regulating menstruation” General H
“When I have an attack, I cannot walk, wash or groom myself”. Physical fu
“I had to give up medication because of virilization symptoms” Aesthetics
Note: *Verbatim reports and items were translated from original Spanish into Englisa group of 8 HAE-C1-INH experts and subsequently by
a group of 16 HAE-C1-INH patients, all from different
regions of Spain (expert and patient rating phase). Here,
the sample was also a convenience one, in which sub-
jects were selected in order to include a representativeItem*
nditions How often have you felt that health professionals do not
know about your disease?
l role How much do you worry about the transmission of the
disease to your children?
How has your disease limited your traveling?
alth To what extent does your disease make you feel anxious
or fearful?
t How much are you worried about the adverse side effects
of treatment?
le How has your disease affected your work or studies during
the last six months?
ealth Have you had problems in receiving adequate treatment
for other diseases (drugs for arterial hypertension, oral
contraceptives, and other hormonal treatments) due to
hereditary angioedema?
nctioning Have your angioedema episodes prevented you from
accomplishing basic activities of daily life (washing, eating,
walking, etc. ?
Have you been affected by the possibility of suffering
changes in your physical appearance due to the side
effects of attenuated androgens?
h for this article.
Table 5 Category definitions and number of items per category in HAE−QoL questionnaire
Domain Definition N° of items N° of items
HAE-QOL v 1.0 HAE-QOL v 1.1
Health conditions To what extent the availability of adequate assistance from health services
and the information (related to prevention and treatment) offered by health
personnel affects daily life.
11 4
Physical functioning To what extent HAE-C1-INH limits physical activities like self-care, grooming,
walking, etc.
2 1
Social role To what extent HAE-C1-INH interferes with normal social life and leisure
activities (including sports, traveling, hobbies).
5 3
Emotional role To what extent HAE-C1-INH affects emotional state/partnership/family. 3 3
Symptoms Objective questions about clinical characteristics of the patient 8 0*
Physical role To what extent HAE-C1-INH interferes with work, studies, or other daily activities,
including a worsened performance in these activities, a limitation in the type of
activities that can be performed, or difficulties in undertaking of these activities.
7 7
Aesthetics To what extent the disease affects physical appearance and aesthetic habits. 2 1
General health To what extent personal health assessment including current health, health
perspectives for the future, resistance to disease and the influence of HAE-C1-INH
on other aspects of health.
3 3
Mental health To what extent general mental health, including depression, anxiety, and behavioral
and emotional control are affected by HAE-C1-INH.
12 11
Treatment To what extent HAE-C1-INH treatment affects daily life, regarding disease control,
side-effects, availability of treatment.
11 11
* Symptoms dimension was substituted by a supplementary clinical questionnaire.
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sex, age, level of studies, geographical origin and severity
of disease. A standardized evaluation form was used
by experts to assess clarity of the items, relevance for
HAE-C1-INH and assignment of dimensions. The con-
dition established for deciding to keep, reformulate or
remove items was an agreement rate of 80%. Qualita-
tive comments suggesting that items be edited or added
were also taken into account. Following the expert
evaluation, 21 items were removed, 1 was added, 30
were reworded, and 6 items were reassigned to another
dimension. Researchers agreed to remove the clinical di-
mension of the questionnaire and add a supplementary
specific HAE-C1-INH clinical questionnaire specially
developed for this study in order to obtain objective
clinical data. Another major reason for removal was to
avoid the use of similar items or to eliminate ambiguous
or poorly worded items. No items were deemed irrele-
vant. Of the 30 items that were modified, 12 were for an
agreement rate of 25%, 2 for a 37.5%, 1 for a 50% and in
14 items as result of qualitative comments. The resulting
44 item version was evaluated by the patients for clarity
and relevance. Their evaluation resulted in the deletion
of 1 item (due to qualitative comments), the modifica-
tion of 8 items (1 item with an agreement rate of
31.25%, 3 with a 25% and 4 items due to qualitative
comments) and the addition of 1 item. None of the
items were removed due to a lack of relevance in either
evaluation. Demographic characteristics and severity
scores of the patients who participated in the semi-structured interview phase and rating phase are shown
in Table 6.
The preliminary version of the questionnaire (HAE-QOL
v 1.1.) contained 44 items compiled into 9 domains. Exam-
ples of the expert and patient rating phase are shown in
Tables 7 and 8.
In the second phase (working in progress) the prelim-
inary version of the questionnaire presented here will
undergo a complete validation process. A psychometric
field study will be performed with HAE-QoL v 1.1,
SF-36v2 and the specific HAE-C1-INH clinical question-
naire in a sample of HAE-C1-INH patients. Demo-
graphic data of the participating patients will also be
obtained. Statistical analysis will be performed with the
program SPSS/PC Program. Descriptive and psychomet-
ric analysis of the questionnaire HAE-QoL will also be
performed. The psychometric study will assess data qual-
ity (including missing values), scaling assumptions (item
variance, item-total correlation, multi-trait/multi-item
correlation matrix), reliability (internal consistency and
test-retest with calculation of Crombach’s alpha and
intraclass correlation index) and evidence for validity.
The association between HRQoL as measured by
HAE-QoL and different factors that could affect HRQoL
will be assessed using Mann–Whitney U test, Krushal-
Wallis test or Spearman correlation, as appropriate.
Discussion
Disease-specific measures to assess HRQoL in HAE-
C1-INH patients have not been available until now.
Table 6 Characteristics and Severity Score of participating HAE-C1-INH patients (convenience representative sample)
Semi-structured interview phase Patient rating phase
N° patients 45 16
Sex 29 women/16 men 8 women/8 men
Age 18-74 years old (mean age 39) 23-55 years old (mean age 37.4)
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ing a disease-specific QoL questionnaire for adults
with HAE-C1-INH as part of a national multi-centre
research project. Such an instrument can provide a
more comprehensive and accurate evaluation of the
HRQoL status of HAE-C1-INH patients and insights
on how the illness affects their daily life. Moreover, it
could be an instrumental tool for building health pol-
icies or implementing measures to improve the health
and well-being of patients with HAE-C1-INH.
The methodological approach of this study is premised
on the idea that a patient´s perception of illness and
related impairments is a key issue to consider when
assessing HRQoL [37]. Opinions of HAE-C1-INH
experts were also used as the basis for item selection.
Items were modified or removed based on the responses
and feedback provided by patients and experts in order
to ensure content validity. Our goal was to create an in-
strument that patients considered thorough, respondent-
friendly and useful for expanding our knowledge of the
impact of HAE-C1-INH on HRQoL.
HAE-C1-INH patients and experts were recruited from
different regions of Spain in an attempt to gather a var-
iety of perspectives in a country known for its significant




29 Physical Role How often has the disease prevented you from
your work or studying properly?
52 Symptoms Have you been affected by not knowing how s
an episode of swelling would be?
14 Physical functioning How often has angioedema impeded your abil
carry out planned activities?
56 Treatment How often have you worried about the possibi
treatment would not be available when you ne
13 Treatment To what extent have you felt more at ease afte
begun treatment?
A: Clarity and adequate wording – item was revised if agreement rate was below 8
was removed if agreement rate was below 80%C: Need for rephrasing/modifying t
D: Correct domain- item was moved if agreement rate was below 80%. * These exa
Qualitative comments.addressed several dimensions of quality of life on which
to base a thorough evaluation. The domain framework
is provisional and represents our theoretical model.
While the definition or scope of categories (domains)
may seem to overlap, future psychometric test results
will help us to decide whether to leave the categories as
they are or group some of them together under a single
broader domain.
Over the last few years, HRQoL has emerged as an
important outcome measure of the degree of patient suf-
fering, as well as a tool for comparing the efficacy of dif-
ferent treatments and assessing the results of health
policy planning. However, this outcome measure is of
little value if the instruments employed lack validity
or reliability.
Although generic HRQoL questionnaires are readily
available, they often lack the specificity necessary to ad-
equately measure how certain aspects of a disease are
related to QoL. In such cases, a disease-specific ques-
tionnaire would be preferable.
Data linking HAE-C1-INH to a burden on quality of
life has been available for some time [38], however this
is the first time that data has been collected using semi-
structured questions. Huang et al. [25] showed that 46%
of HAE-C1-INH patients were dissatisfied with therates in expert rating phase
A (%) B (%) C (%) D (%) Final Decision
doing 100% 100% 0% 100% Maintained
evere 75% 87.5% 37.5% 100% Modified/Reassigned
dimension (to Mental Health)




87.5% 100% 0% 100% Maintained
r having 62.5% 100% 50% 87.5% Removed (QC, similar to and
better wording in item 62)
0% or by consensus in qualitative comments. B: Relevant for HAE-C1-INH - item
he item- item was reworded if agreement rate was over 20%.
mples were translated from the Spanish to English for this paper. QC:
Table 8 Examples of items and agreement rates in patient rating phase
Item
no.
Subscale Example (*) A (%) B (%) Final Decision
33 General Health To what extent have you been prevented from using other
treatments (ACE antihypertensives, oral contraception, . . .)
due to HAE?
75% 100% Modified (QC also taken
into account)
41 Mental Health To what extent have you felt at ease after obtaining the
HAE diagnosis?
87.5% 93.75% Removed based on QC
23 Physical Role How often have you missed work or school/classes because
of an angioedema attack?
100% 100% Maintained
26 Aesthetics To what extent have you been affected by the impact of
secondary adverse events of attenuated androgens treatment
in your physical appearance?
68.75% 100% Modified
6 Health Conditions To what extent have you been affected by the need to get
to a health care center to receive medication for acute attacks?
81.25% 93.75% Modified based on QC
17 Social Role To what extent has this disease affected you in terms of taking
trips or traveling?
100% 100% Maintained
A: Clarity and adequate wording – item was revised if agreement rate was below 80% or by consensus in qualitative comments. B: Relevant for HAE-C1-INH - item
was removed if agreement rate was below 80%.
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airway closure and 65% had a fear of pain. Other studies
revealed that disruptive attacks caused patients to miss
opportunities for career and personal development and
they may have failed to reach their full potential because
of high anxiety levels and depression [26-28].
In our study, the issues cited most often by both
experts and patients include potentially life-threatening
attacks; the adverse side effects of medication (in several
cases associated with chronic treatment); the unavailabil-
ity of acute specific treatment at several health care cen-
tres; hereditary transmission; the lack of a known trigger
to be avoided in many cases; and the fact that it is a rare
disease about which health care professionals know very
little. It is especially worth noting that the relevant
aspects of HAE-C1-INH were not the same for experts
and patients. Aesthetics was an aspect mentioned more
often by patients than by experts. On the other hand,
experts were more likely to mention the adverse side
effects of treatment. This finding supports the general
opinion that the clinician´s view of disease severity does
not necessarily match with the patient´s perception of
disability. Thus, measuring HRQoL impairment could
become an important part of HAE-C1-INH manage-
ment. Moreover, the recent HAE-C1-INH International
Working Group consensus has recommended yearly
assessments be carried out using a HRQoL question-
naire [12].
There is limited data available on HRQoL in patients
with HAE-C1-INH. Lumry et al. [28] administered the
SF-12 to patients and found that HAE-C1-INH created
a considerable humanistic burden across physical and
mental health domains. HAE-C1-INH patients also
had higher mean scores than population norms in the
Hamilton Depression Inventory-Short form (HDI-SF).
Over 42% scored >8.5, which is indicative of depressivesymptomatology. A determinant factor for depression
was the severity of the disease. Patients who were
under long term prophylactic treatment with attenuated
androgens were shown to report even lower levels of
HRQoL when compared with the overall HAE-C1-INH
population.
Dermatology Life Quality Index (DLQI), SF-36, and an
adaptation of the Pain Disability Index have been used
in HAE-C1-INH patients [26,27], but none of these
questionnaires, including the SF-12, have been specific-
ally developed or validated for HAE-C1-INH.
The HAE-QoL questionnaire is a disease-specific
HRQoL measure that could be used in future research
on clinical and economic matters and the identifica-
tion of the determinants of HRQoL in HAE-C1-INH.
This information could thereby aid health care pro-
viders and professionals in their quest to design and
implement measures for improving the HRQoL of
HAE-C1-INH patients.
The next step in the HAE-QoL project will be to set
up a field study using the draft questionnaire (HAE-QoL
v. 1.1). We will assess data quality, scaling assumption,
reliability and evidences for validity.
Lastly, the final phase of this protocol will be to per-
form a HRQoL study with the final version of the vali-
dated questionnaire. Assessments of HRQoL can be
repeated at different times in order to discover how
changes in the management of the disease and
changes in drug availability influence the HRQoL of
HAE-C1-INH patients. We believe this is the first multi-
centre research project designed to develop a specific in-
strument to assess HRQoL in adults with HAE-C1-INH.Competing interests
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